Ann: Oncolytic Virotherapy CF33 Patent Granted in Japan, page-65

This is a copy and why paste of my post in the Bagger thread a few days ago. People need to listen to management and stop guessing what is going on. It's always been about collaborations and combinations. It was never about get through phase 2 and into 3. LC keeps us well informed, it's a matter of what we want to listen to


Slow and steady always wins the race. The most recent collaborations with our platforms with BP are purely about advancing our brand far ahead of where many realise IMO.Looking at trialling in untreated patients before they have had chemo etc is about disrupting the long held beliefs about how cancer needs to be treated. It's notonky about proving our products work either alone or in conjunction with other drugs, but more so other drugs when used alongside our products can change the whole method and ideology of how treatments for cancer patients need to proceed.Doing what we are doing proves our platforms at the expense of BP. If we can prove our products can be used front and centre as a treatment for cancer without chemo/surgery that is a win for us alone. If BP thought their drugs could be used this way they would already be pushing it. The fact is they can't! If in combination they can it proves our platforms can.If our platforms can prove this, it will open up other manufacturers to want to collaborate with us for their gain and ultimately ours. If our platforms become part of the first line of treatment for cancer, drug companies will be ringing us to collaborate and not us making the calls.LC, PH, YF and team have a grand plan and have always been about collaborations and changing the way cancer is treated. The longer the fame is played the closer we get to the ultimate goal, a paradigm shift. Follow the science and ot the white noise.DYOR